Ahmar U. Zaidi/LinkedIn
Jun 14, 2026, 18:01
Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
Ahmar U. Zaidi, Senior Medical Director of Clinical Development at Agios Pharmaceuticals, shared a post on LinkedIn:
“EHA plenary for the RISE UP study!
An incredible moment.
Not because the RISE UP study was on one of the biggest stages in hematology, but because of what it represented.
The first pivotal study of a new mechanism in Sickle Cell disease. The chance to help tell the story of a potential new treatment paradigm in sickle cell disease: PK activation.
There is immense gratitude for the patients, families, investigators, advocates, and colleagues who made this moment possible.
Progress in sickle cell disease belongs to all of them.
I am simply fortunate to be here while their story is told.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation
-
Nov 8, 2026, 05:34Eugene Bolotin: Thrombosis and Survival in Pancreatic Cancer